

## **REMARKS**

### **Restriction Requirement**

The Office Action required restriction of pending claims 17-35, 39 and 40 to one of two allegedly patentably distinct inventions. Applicants elect without traverse the invention identified as "Group I" in the Office Action, drawn to GNRH analogues. Group I presently includes claims 17-30 and 39.

### **Notice to Comply**


A Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice") was mailed together with the Office Action. Applicants submit that a sequence listing in both paper and computer readable copies was submitted and entered on February 5, 2007, as indicated in the Image File Wrapper and Transaction History in the Patent Application Information Retrieval (PAIR) database. Applicants also thank Examiner Bradley for the telephonic interview with James A. Culverwell on May 22, 2007, regarding the Notice. During the interview, Examiner Bradley confirmed that the application is in compliance with the rules relating to nucleotide and amino acid sequences (37 C.F.R. §§ 1.821-1.825) and that no action is required at this time in response to the Notice.

Therefore, Applicant respectfully submits that the Application fully complies with 37 C.F.R. §§ 1.821-1.825 and request the Notice to be withdrawn.

## **SUMMARY**

Examiner Bradley is invited to telephone the undersigned attorney to discuss any remaining issues. Early and favorable action is respectfully solicited.

Respectfully submitted,



Fangli Chen, Ph.D.  
Attorney for Applicants  
Kirkpatrick & Lockhart Preston  
Gates Ellis LLP  
State Street Financial Center  
One Lincoln Street  
Boston, Massachusetts 02111-2950

Date: May 25, 2007  
Reg. No. 51,551

Tel. No.: (617) 261-3198  
Fax No.: (617) 261-3175